Gerbera Therapeutics, Inc.
🇺🇸United States
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
Phase 2
Recruiting
- Conditions
- Depression, PostpartumPost-partum DepressionPostnatal DepressionPostpartum DepressionPost-Natal Depression
- Interventions
- Drug: NORA520 Dose 1Drug: NORA520 Dose 2Drug: Placebo
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- DuKang Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06285916
- Locations
- 🇺🇸
Pillar Clinical Research, Bentonville, Arkansas, United States
🇺🇸Advanced Research Center, Anaheim, California, United States
🇺🇸Alliance Research Institute, Canoga Park, California, United States